Press Releases

UNION therapeutics A/S ("UNION") announced the completion of an agreement with TFF Pharmaceuticals, Inc. ("TFF") to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19. Niclosamide was recently identified by Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-191. For a number of years, UNION has wo

Beroni Group , is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript Biotech Corporation (HKSE: 1548) (“Genscript”), a company listed on the Hong Kong Stock Exchange, to conduct antibody characterization and optimization through humanization and affinity maturation with the objective of increasing the antibody affinity to ta

Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced that it has taken assignment to certain microbial intellectual property, and has non-exclusively licensed foundational CRISPR-Cas9 intellectual property controlled by Caribou Biosciences, a leading CRISPR genome editing company, to expand its therapeutic pipeline and platform capabilities. “This is an important milestone for Novome that shoul

Avobis Bio, LLC (Avobis Bio), a clinical-stage regenerative therapy company specializing in the development of implantable cell therapies, and Vineti, Inc., the leading software platform for personalized therapeutics, announced a new collaboration to advance and scale Avobis Bio’s innovative cell therapy pipeline. Avobis Bio’s first therapeutic involves harvesting and processing a patient's own mesenchymal stem cells for the treatment of perianal fistulas, an often d

Sarepta Therapeutics Inc., the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs. “We have developed a productive incubator ap

CPhI South East Asia – organised by Informa Markets – has been rescheduled to May 18-20, 2021 to give the ASEAN pharma community more time to recover and to mitigate any global disruptions caused by COVID-19. “The decision to reschedule the event to 2021 reflects changing attendee needs. By moving to spring next year, we will enable exhibitors and visitors to get the maximum amount of value from the show. A 2021 CPhI South East Asia will deliver reassurance to our

Dragonfly Therapeutics, Inc announced that Bristol Myers Squibb ("BMS") has announced its fourth TriNKET ™ immunotherapy drug candidate from Dragonfly has licensed. Since the initial collaboration in 2017, which focused on hematologic malignancies, the two companies have agreed to two more collaborations for solid tumors and autoimmune diseases. "We are impressed with the quality of the candidates developed with Dragonfly's TriNKET ™ technology,&q

Ligand Pharmaceuticals Incorporated and Pfenex Inc.announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis. In addition, Ligand will pay $2.00 per share or $78 million as a Contingent Value Right (CVR) in the event a predefined regulatory milestone is achieved by December 31, 2021, for a total transaction value of up to $516 million. The closing of this transact

The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. BRaVac is an international, multi-centre study, which wil

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine (“LSTM”) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva. LSTM has been at the forefront of research into infectious, debilitating and disabling diseases since 1898 and was the first institution in the world dedicated to res